Table 1 Comparison of the proportions of TDM implementation for each anti-MRSA agent after propensity score matching when classified into pediatric patients (under 18-years old) and non-pediatric patients (18 years and older)
Description | Ward pharmacy service group | Non-ward pharmacy service group | P-value |
|---|---|---|---|
Vancomycin | |||
Pediatric patients, n/n (%) | 106/179 (59.2) | 105/207 (50.7) | 0.095 a) |
Non-pediatric patients, n/n (%) | 487/678 (71.8) | 412/650 (63.4) | 0.001 a) * |
Teicoplanin | |||
Pediatric patients, n/n (%) | 35/87 (40.2) | 22/102 (21.6) | 0.005 a) * |
Non-pediatric patients, n/n (%) | 79/135 (58.5) | 55/120 (45.8) | 0.043 a) * |
Arbekacin | |||
Pediatric patients, n/n (%) | 2/17 (11.8) | 5/20 (25.0) | 0.417 b) |
Non-pediatric patients, n/n (%) | 9/35 (25.7) | 7/32 (21.9) | 0.713 a) |